Navigation Links
MGC Diagnostics Corporation Announces Partnership with Frontera Strategies, LP
Date:2/27/2013

SAINT PAUL, Minn., Feb. 27, 2013 /PRNewswire/ -- MGC Diagnostics Corporation (NASDAQ: MGCD) (formerly Angeion Corporation), a global medical technology company, today announced it has entered into a partnership with Frontera Strategies, LP ("Frontera"), the leading provider of in-office cardiac, pulmonary, vascular and neurological testing services. As a result of this partnership, Frontera has agreed to purchase new cardiopulmonary diagnostic equipment with customized systems developed and designed by MGC Diagnostics to better meet the demanding requirements of Frontera's mobile testing procedures. Based in Irving, Texas, Frontera Strategies has been recognized by Modern Healthcare as one of the "Best Places to Work" in the healthcare industry.

(Logo: http://photos.prnewswire.com/prnh/20120821/LA60189LOGO)

MGC Diagnostics, ranked 'Best-In-Class' by MD Buyline's User Satisfaction Report, is focused on providing non-invasive diagnostic systems with unmatched service and support throughout the U.S. and internationally.

Kai Pinkerton , Clinical Operations Manager of Frontera, commented "We chose MGC Diagnostics because of their product quality, service excellence and attractive company culture. Clinically we were pleased with the products and MGC Diagnostics was flexible enough to work out a winning solution for us. At Frontera the experience for our patients and customers is our number one priority. Partnering with MGC Diagnostics, who leads their industry in service excellence, was a natural fit."

Richard Baker , Co-founder and Partner of Frontera, added "As a leader in mobile diagnostic services, we are excited to partner with MGC Diagnostics to better serve our customers and their patients within the Oklahoma and Texas markets. Our goal is to be a thought leader in driving down healthcare costs and we are looking for ways to bring better, more cost efficient diagnostic testing to the marketplace."

Gregg O. Lehman , Ph.D., Chief Executive Officer and President of MGC Diagnostics, commented "We are pleased to have been chosen by Frontera to assist them in maintaining a leadership role in mobile testing. As part of our efforts to improve patient outcomes and reduce healthcare costs, we remain committed to providing innovative diagnostic equipment to mobile testing services focused at physicians' offices, as well as at traditional healthcare facilities."

About Frontera Strategies
Frontera is the leading provider of in-office cardiac, pulmonary, vascular and neurological testing services. With more than 2,000 partners across Texas and Oklahoma, Frontera serves physicians in Dallas, Ft. Worth, Austin, Houston, San Antonio, Lubbock, Amarillo, Oklahoma City and Tulsa.  Frontera was founded in 2001 by partners Richard Baker , Nate Nelson and Ches Williams .  For more information, please visit: http://www.teamfrontera.com.

About MGC Diagnostics
MGC Diagnostics Corporation (NASDAQ: MGCD), (formerly Angeion Corporation), is a global medical technology company dedicated to cardiorespiratory health solutions. MGC Diagnostics develops, manufactures and markets non-invasive diagnostic systems. This portfolio of products provides solutions for disease detection, integrated care, and wellness across the spectrum of cardiorespiratory healthcare. The Company's products are sold internationally through distributors and in the United States through a direct sales force targeting heart and lung specialists located in hospitals, university-based medical centers, medical clinics, physicians' offices, pharmaceutical companies, medical device manufacturers, and clinical research organizations (CROs). For more information about MGC Diagnostics, visit www.mgcdiagnostics.com.

Cautionary Statement Regarding Forward Looking Statements
From time to time, in reports filed with the Securities and Exchange Commission, in press releases, and in other communications to shareholders or the investing public, MGC Diagnostics Corporation may make forward−looking statements concerning possible or anticipated future financial performance, business activities or plans that include the words "believes," "expects," "anticipates," "intends" or similar expressions. For these forward−looking statements, the Company claims the protection of the safe harbor for forward−looking statements contained in federal securities laws. These forward−looking statements are subject to a number of factors, risks and uncertainties, including those disclosed in our periodic filings with the SEC, that could cause actual performance, activities or plans after the date the statements are made to differ significantly from those indicated in the forward−looking statements. For a list of these factors¸ see the sections entitled "Risk Factors" and "Cautionary Note Regarding Forward Looking Statements," in the Company's Form 10-K for the year ended October 31, 2012, and any updates in subsequent filings on Form 10-Q or Form 8-K under the Securities Exchange Act of 1934.Contact:Gregg O. Lehman, Ph.D.Joe Dorame, Robert Blum, Joe DiazMGC Diagnostics CorporationLytham Partners, LLCChief Executive Officer(602) 889-9700(651) 484-4874mgcd@lythampartners.com


'/>"/>
SOURCE MGC Diagnostics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. QBC Diagnostics Awarded GSA Contract
2. Quest Diagnostics Establishes Unique Healthcare Identifier to Improve Access to Vital Patient Health Information; 80 Million Patient IDs Created to Date
3. Heightened Awareness, Coupled with Expanding Patient Pool, Stimulates Sleep Apnea Diagnostics and Sleep Services Market, Says Frost & Sullivan
4. Ariosa Diagnostics to Present and Exhibit at the 16th International Conference on Prenatal Diagnosis and Therapy
5. ZINO Society Targets Medical Devices, Healthcare IT and Diagnostics
6. Quest Diagnostics To Speak At The Wells Fargo Securities 2012 Healthcare Conference
7. Breakthrough Prostate Cancer Diagnostics
8. NicOx Signs Worldwide Licensing Agreement With Rapid Pathogen Screening, Inc. For Ophthalmic Diagnostics
9. Frost & Sullivan: Expanding Sample Prep Market Supports Growth Trends in Molecular Diagnostics Markets
10. QIAGEN Unveils Initiative to Create Next-Generation Sequencing Portfolio for use in Clinical Research and Molecular Diagnostics
11. Quest Diagnostics to Release Second Quarter 2012 Financial Results on July 19
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... 2016 Research and Markets has announced the ... their offering. ... R&D Drug Pipeline Database: 1-Year ... Drug Pipeline Database provides 24/7 online access to information about more ... and on investigational drug candidates in research & development. ...
(Date:12/2/2016)... , December 2, 2016 bioLytical Laboratories, un líder mundial ... el INSTI HIV Self Test , a los miembros de la Kenya ... ... INSTI HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical fue ...
(Date:12/2/2016)...  LifeVac, the revolutionary device that has successfully rescued ... Training and Support Services (ERTSS) training programs. ... part of the ERTSS mission to save lives," said ... "Having an established network of expert trainers demonstrating how ... our efforts to spread LifeVac,s message that choking deaths ...
Breaking Medicine Technology:
(Date:12/4/2016)... ... December 03, 2016 , ... While James Earl Jones is known for myriad ... a show called "Front Page". One of the forthcoming episodes examines mammogram techniques; a ... plummeted in large part due to early detection. Like any other disease, treatments have ...
(Date:12/4/2016)... CA (PRWEB) , ... December 04, 2016 , ... ... without undergoing major cosmetic surgery can now take advantage of a cosmetic procedure ... advanced skin rejuvenation treatment that reduces the appearance of age spots, fine ...
(Date:12/2/2016)... ... 02, 2016 , ... Lori G. Cohen and Sara K. ... at the American Conference Institute’s 21st Drug & Medical Device Litigation Conference , ... of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical Device & Health ...
(Date:12/2/2016)... ... December 02, 2016 , ... More than 100 ... are expected to attend the UNCF Dothan-Wiregrass Mayor’s Luncheon Dec. 9, 2016. This ... area students and operating support to UNCF-member institutions, including Miles College, Oakwood University, ...
(Date:12/2/2016)... , ... December 02, 2016 , ... The annual time ... Period (or Annual Election Period), is ending December 7th. Currently-enrolled Medicare beneficiaries who are ... or prescription drug plan (Part D) need to make changes during this period order ...
Breaking Medicine News(10 mins):